Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
88
resultados
Última actualización
27/09/2024 [09:20:00]
Resumen de: WO2024192346A1
Technologies for providing immunogenic compositions (e.g., vaccines) and methods of inducing immune responses in subjects in need thereof.
Resumen de: US2024307523A1
A coronavirus vaccine based on controllable secretory expression of attenuated Salmonella, a preparation method therefor, and use thereof. The method includes constructing controllable and stable expression plasmids for secretory expression of different antigenic structural domain proteins of the new coronaviruses and their attenuated Salmonella expression strains, and then mixing various attenuated Salmonella antigen-presenting strains that can achieve controllable intracellular secretory expression in antigen-presenting cells. With the aid of a unique secretion system, a variety of different antigenic proteins can be secretory-expressed efficiently in antigen-presenting cells after oral gavaging. The secretory-expressed antigenic proteins can be efficiently processed and presented by the antigen-presenting cells, and finally activate/regulate the immune system to produce more potent antibodies to make the vaccine work.
Resumen de: US2024309074A1
Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble.
Resumen de: CN118652815A
本发明公开了一株禽源鼠伤寒沙门氏菌ST0602及其应用，该菌株已进行保藏，保藏单位：中国典型培养物保藏中心；地址：武汉大学；保藏日期：2024年5月30日；保藏编号：CCTCC NO.M 20241100。本发明还提供了所述的鼠伤寒沙门氏菌用于构建禽用弱毒疫苗株的应用。鼠伤寒沙门氏菌ST0602对目前常见抗菌药物均敏感，且遗传稳定性好，适合于构建鼠伤寒沙门氏菌减毒活疫苗株。
Resumen de: CN118652816A
本发明公开了一株禽源鸡白痢沙门氏菌SP0936及其应用，该菌株已进行保藏，保藏单位：中国典型培养物保藏中心；地址：武汉大学；保藏日期：2024年5月30日；保藏编号：CCTCC NO.M 20241098。本发明还提供了所述的鸡白痢沙门氏菌用于构建禽用弱毒疫苗株的应用。鸡白痢沙门氏菌SP0936对20种常见抗菌药物均敏感，且遗传稳定性好，适合于构建鸡白痢沙门氏菌弱毒疫苗株。
Resumen de: CN118638833A
本发明公开了一种肠炎沙门菌pipC基因缺失菌株及其应用。涉及基因工程技术领域。提供了其构建方法、应用。本发明通过体外应激试验，发现pipC基因缺失株抵抗酸，碱和氧化应激能力显著降低；通过细胞侵袭及胞内存活试验，发现pipC基因缺失后肠炎沙门菌的侵袭能力和胞内存活能力显著降低，证明pipC基因与侵袭相关。通过小鼠半数致死量和器官载菌量试验，发现pipC基因影响肠炎沙门菌的毒力；同时通过免疫保护试验和淋巴细胞转化试验，结果显示pipC缺失株对小鼠具有显著的免疫保护能力；通过检测细胞因子水平的变化和检测IgG、IgA的水平，结果显示，pipC缺失株免疫后小鼠的细胞免疫和体液免疫水平显著上升。
Resumen de: US2024299522A1
Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.
Resumen de: EP4427755A1
The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients. The composition of the present invention may be useful as a prophylactic or therapeutic composition of improving the survival rate by significantly reducing the tumor size by co-administering bacteria and an immune checkpoint inhibitor in cancer, especially a type of cancer that is resistant and difficult to treat by a single anticancer therapy.
Resumen de: MX2024005116A
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: CN117700500A
The present invention relates to a mutated form of lipoprotein CsgG, in particular the modification at one or more positions in Tyr51, Asn55, and Phe56, which is located in an external mode. The invention also relates to analyte detection and characterization using said mutant CsgG.
Resumen de: WO2024180083A1
The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an autotransporter comprising transmembrane linker and a trans- porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
Resumen de: US2024294994A1
Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.
Resumen de: US2024293524A1
The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.
Resumen de: MX2024005116A
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: FR3145866A1
L’invention a trait au domaine des compositions vaccinales. Elle concerne plus particulièrement une composition vaccinale prophylactique à destination des mammifères et des oiseaux comprenant une bactérie entière tuée, ladite bactérie étant recouverte d’un agent cationique, en particulier des nanoparticules cationiques.
Resumen de: FR3145867A1
L’invention a trait au domaine des compositions vaccinales. Elle concerne plus particulièrement une composition vaccinale prophylactique à destination des mammifères et des oiseaux comprenant une bactérie entière tuée, ladite bactérie étant recouverte d’un agent cationique, en particulier des nanoparticules cationiques.
Resumen de: US2024277824A1
The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.
Resumen de: WO2024170728A1
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: WO2024167300A1
The present invention relates to an anti-cancer Salmonella strain and an anti-cancer composition comprising same, the strain being targeted to tumor cells, and then secreting a protein that induces necrosis so as to cause necrosis of the tumor cells, while exhibiting greater anti-cancer immune activity, and, more specifically, to a Salmonella strain and a an anti-cancer composition comprising same, the strain being transformed with a gene construct that includes a flhDC gene and a gene construct that encodes an MLKL protein or an MLKL protein fragment including the N-terminal sequence.
Resumen de: CN118496328A
本发明公开了利用SadA蛋白在沙门氏菌中表面呈现表达外源抗原的方法与应用。本发明公开的方法包括将目的蛋白的编码基因插入至SadA蛋白或其截短体的编码基因中得到重组基因，将重组基因与SadB蛋白的编码基因导入沙门氏菌中，并使各基因得到表达，实现目的蛋白在沙门氏菌表面的表达。利用本发明的SadA蛋白或其截短体与SadB蛋白，在减毒鼠伤寒沙门氏菌呈现表达幽门螺杆菌尿素酶B核心区域片段，获得的重组菌免疫小鼠后能够激发其产生针对尿素酶B的特异性的IgG和sIgA，具有良好的免疫原性。说明，SadA蛋白或其截短体与SadB蛋白可作为一种新的抗原表面表达系统，用于减毒活载体疫苗的研究。
Resumen de: US2024269257A1
Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites). Also provided are vaccine compositions (medicaments) containing a pathogen inactivated by exposure to an inactivating agent in the presence of elevated concentrations of inorganic polyatomic oxyanions, and methods for eliciting an immune response in a subject by administering the vaccine compositions.
Resumen de: WO2024165442A1
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2024167300A1
The present invention relates to an anti-cancer Salmonella strain and an anti-cancer composition comprising same, the strain being targeted to tumor cells, and then secreting a protein that induces necrosis so as to cause necrosis of the tumor cells, while exhibiting greater anti-cancer immune activity, and, more specifically, to a Salmonella strain and a an anti-cancer composition comprising same, the strain being transformed with a gene construct that includes a flhDC gene and a gene construct that encodes an MLKL protein or an MLKL protein fragment including the N-terminal sequence.
Resumen de: US2024261382A1
A modified bacterium, a preparation method thereof and an application thereof. The modified bacterium comprises a bacterium body and a poorly soluble or insoluble biologically acceptable metal compound modified on the surface of the bacterium body. After the modified bacterium is injected in a tumor, an anti-tumor immune response can be activated, an excellent anti-tumor treatment is activated, and tumor metastasis and recurrence can be effectively inhibited.
Nº publicación: US2024261311A1 08/08/2024
Solicitante:
REVELATION BIOSCIENCES INC [US]
Revelation Biosciences, Inc
Resumen de: US2024261311A1
The present disclosure provides a method of treating or preventing symptoms of allergic rhinitis or chronic nasal congestion in a subject by administering to the subject an MPLA compound.
BOPI
Sede Electrónica
